Indian Journal of PsychiatryIndian Journal of Psychiatry
Home | About us | Current Issue | Archives | Ahead of Print | Submission | Instructions | Subscribe | Advertise | Contact | Login 
    Users online: 214 Small font sizeDefault font sizeIncrease font size Print this article Email this article Bookmark this page
  My preferences 


This article has been cited by
1Pharmacological management of orofacial pain – a clinician’s guide
M.V. Clark,C.C. Donnell,J. Durham,R. Balasubramaniam
Oral Surgery.2020;13(4)422
2Antidepressants and Risk of Sudden Cardiac Death: A Network Meta-Analysis and Systematic Review
Narut Prasitlumkum,Wisit Cheungpasitporn,Nithi Tokavanich,Kimberly R. Ding,Jakrin Kewcharoen,Charat Thongprayoon,Wisit Kaewput,Tarun Bathini,Saraschandra Vallabhajosyula,Ronpichai Chokesuwattanaskul
Medical Sciences.2021;9(2)26

Effect of Depression and Antidepressants on Sexual Dysfunction in Men with Diabetes: A National Population-Based Cohort Study

Pei-Lun Chung,Chien-Wei Huang,Min-Jing Lee,Yao-Hsu Yang,Ko-Jung Chen,Mong-Liang Lu,Jun-Cheng Weng,Vincent Chin-Hung Chen
Neuropsychiatric Disease and Treatment.2020;Volume 16(2)1105
4Polymorphism 3435c> t of the ABCB1 gene (rs1045642) does not affect the mirtazapine efficiency and safety profile in patients with depressive disorders comorbid with alcohol use disorder
M. S. Zastrozhin,E. A. Grishina,K. A. Ryzhikova,V. Yu. Skryabin,S. G. Koporov,E. A. Bryun,D. A. Sychev
Bulletin of Siberian Medicine.2021;19(4)73
5Antidepressant-like effect of Cuminum cyminum essential oil on the forced swim and tail suspension tests in male mice
Kosar Asadi,Saeid Abbasi-Maleki,Goudarz Sadeghi Hashjin
Journal of Shahrekord University of Medical Sciences.2020;22(4)167
6Relationship of cognitive impairment with depressive symptoms and psychosocial function in patients with major depressive disorder: Cross–sectional analysis of baseline data from PERFORM-J
Tomiki Sumiyoshi,Koichiro Watanabe,Shinichi Noto,Shigeru Sakamoto,Yoshiya Moriguchi,Kristin Hui Xian Tan,Lene Hammer-Helmich,Jovelle Fernandez
Journal of Affective Disorders.2019;258(4)172
7ABCB1 and DRD3 polymorphism as a response predicting biomarker and tool for pharmacogenetically guided clozapine dosing in Asian Indian treatment resistant schizophrenia patients
Naveen M,Amol N. Patil,Smita Pattanaik,Anit Kaur,Dibyajyoti Banerjee,Sandeep Grover
Asian Journal of Psychiatry.2020;48(4)101918
8Fibroblast Growth Factor: Promising Target for Schizophrenia
Ali Talaei,Tahereh Farkhondeh,Fatemeh Forouzanfar
Current Drug Targets.2020;21(13)1344
9The Effect of Cyp2d6 Gene Polymorphism on the Efficacy and Safety of Mirtazapine in Patients with Depressive Disorders Comorbid with Alcohol
Mikhail S. Zastrozhin,Valery V. Smirnov,Alexander S. Sorokin,Elena A. Grishina,Kristina A. Ryzhikova,Valery V. Shipitsyn,Ludmila M. Savchenko,Oleg Z. Buzik,Sergey S. Koporov,Evgeny A. Bryun,Dmitry A. Sychev
Annals of the Russian academy of medical sciences.2019;74(3)185
10Frequency, reasons, and factors associated with antipsychotic polypharmacy in Schizophrenia: A retrospective chart review in a tertiary hospital in India
Sonia Shenoy,Amrtavarshini R,Rajeshkrishna P. Bhandary,Samir Kumar Praharaj
Asian Journal of Psychiatry.2020;51(3)102022
11Effects of CYP2C19 genetic polymorphism on the steady-state concentration of citalopram in patients with major depressive disorder
M. S. Zastrozhin,V. Yu Skryabin,A. E. Petukhov,M. V. Torrado,E. P. Pankratenko,A. K. Zastrozhina,E. A. Grishina,K. A. Ryzhikova,V. V. Shipitsyn,E. A. Bryun,D. A. Sychev
The Pharmacogenomics Journal.2021;51(3)102022
12Assessment of the impact of the steady state level of microRNA hsa-miR-370-3p concentration on the efficacy and safety profile of fluvoxamine in patients with depressive disorders disorder comorbid with alcohol use disorders
Mikhail Zastrozhin,Valentin Skryabin,Kristina Ryzhikova,Dmitriy Sychev
Vestnik nevrologii, psihiatrii i nejrohirurgii (Bulletin of Neurology, Psychiatry and Neurosurgery).2020;51(2)37
13Depression treatment use among stroke individuals with depression: A cross-sectional analysis of the Medical Expenditure Panel Survey
Raj Desai,Kalyani Sonawane
Research in Social and Administrative Pharmacy.2019;15(11)1338
14Recent advances in the development of asenapine formulations
Akhil Suresh,Reema Narayan,Usha Y Nayak
Expert Opinion on Drug Delivery.2020;17(10)1377
15Alterations in levels of 8-Oxo-2'-deoxyguanosine and 8-Oxoguanine DNA glycosylase 1 during a current episode and after remission in unipolar and bipolar depression
Deniz Ceylan,Selda Yilmaz,Gamze Tuna,Melis Kant,Ayse Er,Aysegül Ildiz,Burcu Verim,Merve Akis,Pinar Akan,Hüray Islekel,Marin Veldic,Mark Frye,Aysegül Özerdem
16Identification of risk factors and metabolic monitoring practices in patients on antipsychotic drugs in South India
Pooja Gopal Poojari,Sohil A. Khan,Sonia Shenoy,Leelavathi D. Acharya,Sahana Shetty,Swarnali Bose,Keshava Pai,Vijayanarayana Kunhikatta,Girish Thunga
Asian Journal of Psychiatry.2020;53(10)102186
17Oxidative-Antioxidant Imbalance and Impaired Glucose Metabolism in Schizophrenia
Amira Bryll,Justyna Skrzypek,Wirginia Krzysciak,Maja Szelagowska,Natalia Smierciak,Tamas Kozicz,Tadeusz Popiela
18Schizophrenia Psychosis in Women
Mary V. Seeman
19IGF-1 defends against chronic-stress induced depression in rat models of chronic unpredictable mild stress through the PI3K/Akt/FoxO3a pathway
Wei-Hong Kuang,Zai-Quan Dong,Lian-Tian Tian,Jin Li
The Kaohsiung Journal of Medical Sciences.2018;34(7)370
20Treatment of military-related post-traumatic stress disorder: challenges, innovations, and the way forward
David Forbes,David Pedlar,Amy B. Adler,Clare Bennett,Richard Bryant,Walter Busuttil,John Cooper,Mark C. Creamer,Nicola T. Fear,Neil Greenberg,Alexandra Heber,Mark Hinton,Mal Hopwood,Rakesh Jetly,Ellie Lawrence-Wood,Alexander McFarlane,Olivia Metcalf,Meaghan O’Donnell,Andrea Phelps,J. Don Richardson,Nicole Sadler,Paula P. Schnurr,Marie-Louise Sharp,James M. Thompson,Robert J. Ursano,Miranda Van Hooff,Darryl Wade,Simon Wessely
International Review of Psychiatry.2019;31(1)95
21Effects of CYP2D6 activity on the efficacy and safety of mirtazapine in patients with depressive disorders and comorbid alcohol use disorder
M.S. Zastrozhin,V.Y. Skryabin,V.V. Smirnov,E.A. Grishina,K.A. Ryzhikova,E.M. Chumakov,E.A. Bryun,D.A. Sychev
Canadian Journal of Physiology and Pharmacology.2019;97(8)781
22The Outcome of Two Occupational Therapy Group Programs on the Social Functioning of Individuals with Major Depressive Disorder
Enos M. Ramano,Marianne de Beer
Occupational Therapy in Mental Health.2020;36(1)29
23Patterns of care and dropout rates from outpatient mental healthcare in low-, middle- and high-income countries from the World Health Organization's World Mental Health Survey Initiative
Daniel Fernández,Daniel Vigo,Nancy A. Sampson,Irving Hwang,Sergio Aguilar-Gaxiola,Ali O. Al-Hamzawi,Jordi Alonso,Laura Helena Andrade,Evelyn J. Bromet,Giovanni de Girolamo,Peter de Jonge,Silvia Florescu,Oye Gureje,Hristo Hinkov,Chiyi Hu,Elie G. Karam,Georges Karam,Norito Kawakami,Andrzej Kiejna,Viviane Kovess-Masfety,Maria E. Medina-Mora,Fernando Navarro-Mateu,Akin Ojagbemi,Siobhan O'Neill,Marina Piazza,Jose Posada-Villa,Charlene Rapsey,David R. Williams,Miguel Xavier,Yuval Ziv,Ronald C. Kessler,Josep M. Haro
Psychological Medicine.2020;36(1)1
24Pharmacokinetic considerations for current state-of-the-art antidepressants
Elzbieta Wyska
Expert Opinion on Drug Metabolism & Toxicology.2019;15(10)831
25Influence of CYP3A Activity on the Efficacy and Safety of Fluvoxamine in Patients Depressive Disorders and Comorbid Alcohol Use Disorder
Mikhail S. Zastrozhin,Valery V. Smirnov,Alexander S. Sorokin,Elena A. Grishina,Kristina A. Ryzhikova,Inessa A. Bedina,Valery V. Shipitsyn,Ludmila M. Savchenko,Oleg Zh. Buzik,Sergey S. Koporov,Evgeny ?. Bryun,Dmitry A. Sychev
Annals of the Russian academy of medical sciences.2018;73(6)411
26Comparative efficacy of pharmacological treatments on measures of self-rated functional outcomes using the Sheehan Disability Scale in patients with major depressive disorder: a systematic review and network meta-analysis
Bing Cao,Lu Xu,Yan Chen,Dongfang Wang,Yena Lee,Joshua D. Rosenblat,Xiao Gao,Siyan Zhan,Feng Sun,Roger S. McIntyre
CNS Spectrums.2021;73(6)1
27Perceptions of waived juvenile defendants across mental health diagnoses and demographic characteristics
Melanie Taylor,Tatyana Kaplan,Philip Mulvey,Monica K. Miller
International Journal of Law and Psychiatry.2019;66(6)101474
28Consequences of Recurrence of Major Depressive Disorder: Is Stopping Effective Antidepressant Medications Ever Safe?
Jennifer Severe,John F. Greden,Priyanka Reddy
29Consequences of Recurrence of Major Depressive Disorder: Is Stopping Effective Antidepressant Medications Ever Safe?
Miro Jakovljevic
30Antipsychotic treatment in the maintenance phase of schizophrenia: An updated systematic review of the guidelines and algorithms
Yutaro Shimomura,Yuhei Kikuchi,Takefumi Suzuki,Hiroyuki Uchida,Masaru Mimura,Hiroyoshi Takeuchi
Schizophrenia Research.2020;215(2)8
31Effectiveness of a Brief Psychological Intervention Delivered by Nurse for Depression in Pregnancy: Study Protocol for a Multicentric Randomized Controlled Trial from India
Pracheth Raghuveer,Ramdas Ransing,Prerna Kukreti,Mahesh Mahadevaiah,Wafaa Abdelhakim Elbahaey,Satish Iyengar,Harish Pemde,Smita N. Deshpande
Indian Journal of Psychological Medicine.2020;42(6_suppl)S23
32Abnormal Hippocampal Subfields May Be Potential Predictors of Worse Early Response to Antidepressant Treatment in Drug-Naïve Patients With Major Depressive Disorder
Xiaoxiao Hu,Lianqing Zhang,Xinyu Hu,Lu Lu,Shi Tang,Hailong Li,Xuan Bu,Qiyong Gong,Xiaoqi Huang
Journal of Magnetic Resonance Imaging.2019;49(6)1760
33Antipsychotic Polypharmacy
Adriana Foster,Jordanne King
34Factors associated with loss to follow-up of outpatients with depression in general hospitals
Jingjing Zhang,Chenyu Ye
Journal of International Medical Research.2020;48(5)030006052092559